Mylan N.V. (MYL) Receives ‘Analyst’ Rating

Mylan N.V. (MYL) has an average broker rating of 2.33, which is interpreted as a Buy, as rated by 9 equity analysts. Nonetheless, 3 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 6 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Mylan N.V. (MYL) : The consensus price target for Mylan N.V. (MYL) is $57 for the short term with a standard deviation of $6.78. The most optimist securities analyst among the 7 who monitor the stock believes that the stock can reach $66, however, the pessimist price target for the company is $48.


Also, Equity analysts at the Brokerage firm Leerink Swann maintains its rating on Mylan N.V. (NASDAQ:MYL). The rating major has initiated the coverage with outperform rating on the shares. The Analysts at Leerink Swann raises the price target from $51 per share to $55 per share. The rating by the firm was issued on August 15, 2016.

Mylan N.V. (NASDAQ:MYL): After opening at $40.91, the stock dipped to an intraday low of $40.66 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $41.58 and the buying power remained strong till the end. The stock closed at $41.49 for the day, a gain of 1.59% for the day session. The total traded volume was 3,772,754. The stocks close on the previous trading day was $40.84.

Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.